VIGL News and Press, Vigil Neuroscience Inc. From 05/10/24

2024-05-10 15:00:11 ET More on the markets SPY: Growing Signs The Market Is Overbought SPY: The Shrinking Market For U.S. Companies SPY: Stronger Than Ever For the second consecutive week, investors purchase ETFs and conventional funds Earnings estima...

2024-05-08 11:26:11 ET More on Vigil Neuroscience Vigil Neuroscience appoints Kaufmann as Chief Medical Officer Seeking Alpha’s Quant Rating on Vigil Neuroscience Historical earnings data for Vigil Neuroscience Read the full article on Seeking Alpha ...

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside cha...

– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer’s disease ongoing; Interim data analysis on track for mid-2024 – W...

- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology - - Positive interim IGNITE Phase 2 data demonstrating iluzanebart (VGL101) as potential disease-modifying therapy for ALSP WATERTOWN, Mass., Ap...

2024-03-26 15:36:53 ET More on Vigil Neuroscience Vigil Neuroscience appoints Kaufmann as Chief Medical Officer Vigil Neuroscience remains on track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 Seeking Alpha’s Quant Rating on Vig...

– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – E nrollment for IGNITE trial completed with 20 patients enrolled; Next data readout planned for Q3 2024 – ...

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...

2024-03-20 07:50:35 ET More on Vigil Neuroscience Vigil Neuroscience remains on track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 Seeking Alpha’s Quant Rating on Vigil Neuroscience Historical earnings data for Vigil Neuroscienc...

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F...